SOURCE: Journal of Affective Disorders. 333:18-20, 2023 07 15.
AUTHORS: Payette O; Lesperance P; Desbeaumes Jodoin V; Longpre-Poirier C; Elkrief L; Richard M; Garel N; Miron JP
ABSTRACT
BACKGROUND: For individuals with treatment-resistant depression (TRD), transcranial magnetic stimulation (TMS) has become a well-established approach. In the past decade, intravenous (IV) racemic ketamine has also emerged as a potential treatment for TRD. Currently, little data is available on the clinical effects of IV racemic ketamine in TRD patients who experienced TMS-failure.
METHODS: Twenty-one (21) TRD patients who had failed to respond to a standard course of high-frequency left-dorsolateral prefrontal cortex TMS were subsequently scheduled to received IV racemic ketamine infusions. The IV racemic ketamine protocol consisted of 0,5 mg/kg infusions over 60 min, 3 times a week over 2 weeks.
RESULTS: Treatment was safe with minimal side-effects. Mean baseline MADRS score was 27.6 +/- 6.4 (moderate depression), decreasing down to 18.6 +/- 8.9 (mild depression) post-treatment. Mean percent improvement was 34.5 % +/- 21.1 from baseline to post-treatment. Paired sample t-test showed significant MADRS score decrease pre- to post-treatment [t(20) = 7.212, p < .001]. Overall, four (4) patients (19.0 %) responded and two (2) of those achieved remission (9.5 %).
LIMITATIONS: Limitations of this case series include its retrospective and uncontrolled open-label nature, the lack of self-rating and standardized adverse events questionnaires, as well as follow-ups beyond the immediate treatment period.
CONCLUSIONS: Novel ways to increase the clinical effects of ketamine are being explored. We discuss potential combination approaches of ketamine with other modalities to augment its effects. Given the global burden of TRD, novel approaches are needed to curb the current mental health epidemic around the world.
LINK TO FULL ARTICLE: https://www.sciencedirect.com/science/article/abs/pii/S0165032723004809?via%3Dihub
